BioMed Ventures, the corporate venturing unit of the eponymous biotech real estate company, and BASF-backed Fintech Gimv have invested in regenerative medical company Histogenics’s $49m round
Fintech Gimv was joined in the round by venture firm Sofinnova Ventures, which led the round, as well as venture firms Split Rock Partners, ProChon Holdings, Altima Partners, Foundation Medical Partners, and Boston Millennia Partners as well as asset manager Inflection Point Capital.